Trial Profile
A Fremanezumab (TEV-48125) Expanded Access Program for Patients With Migraine
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
- 13 Jul 2020 Status changed from suspended to completed.
- 16 Apr 2020 Status changed from recruiting to suspended.
- 31 May 2018 New trial record